Stock listing

NASDAQ:ZLAB Zai Lab Ltd. Stock

US listing (NASDAQ) of Zai Lab Ltd. · home listing HKEX:9688

Follow Zai Lab Ltd. into a list and get an email when it puts out news.

Share price · NASDAQ:ZLAB

$23.19 USD -0.32 (-1.4%)

Close on Oct 16, 2026

Zai Lab Ltd. logo
Ticker
NASDAQ:ZLAB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Zai Lab (HKEX:9688) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:00 AM ET

    Watch Transcript

  • Zai Lab (HKEX:9688) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:00 AM ET

    Watch Transcript

  • Zai Lab (HKEX:9688) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Monthly return of equity issuer on movements in securities for the month ended 30 September 2026

Oct 5, 2026

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

Jul 22, 2026

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

Jun 8, 2026

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

May 11, 2026

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

Apr 22, 2026

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

Apr 18, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Apr 17, 2026

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Apr 15, 2026

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

Apr 1, 2026

All Zai Lab Ltd. news

Decks

Zai Lab Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 45 in all · newest Oct 5, 2026 · oldest 2025
Calls
21 calls with a replay · 21 with a transcript · latest Aug 6, 2026
Decks
10 decks · latest Aug 6, 2026

Where Zai Lab Ltd. is listed

ListingExchangeCountryCurrency
HKEX:9688 再鼎醫藥 · Home listingHKEXHong KongHKD
NASDAQ:ZLAB · This pageNASDAQUnited StatesUSD
gettex:1ZLgettexGermanyEUR
BOATS:ZLABBOATSUnited StatesUSD
LS Exchange:A3DJSHLS ExchangeGermanyEUR
OTC:ZAILFOTCUnited StatesUSD
Lang & Schwarz:A3DJSHLang & SchwarzGermanyEUR
gettex:1ZLBgettexGermanyEUR
Tradegate:1ZLBTradegateGermanyEUR
Frankfurt:1ZLBFrankfurtGermanyEUR
BMV:ZLABNBMVMexicoMXN
Frankfurt:1ZLFrankfurtGermanyEUR
Tradegate:1ZLTradegateGermanyEUR
Munich:1ZLBMunichGermanyEUR
Dusseldorf:1ZLDusseldorfGermanyEUR
Dusseldorf:1ZLBDusseldorfGermanyEUR
Lang & Schwarz:A2DX1VLang & SchwarzGermanyEUR
LS Exchange:A2DX1VLS ExchangeGermanyEUR
Munich:1ZLMunichGermanyEUR
Stuttgart:1ZLStuttgartGermanyEUR
Stuttgart:1ZLBStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Zai Lab Ltd.